SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Börse
  • Novartis
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012005267 WKN: 904278
    Symbol NOVN.SW
  • Novartis
    Börse Börse München
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Gettex System der Börse München
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Düsseldorf
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Stuttgart
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse München
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Frankfurt
    Symbol NOT
    EUR
  • Novartis
    Börse Quotrix System der Börse Düsseldorf
    Symbol NOTA
    EUR
  • Novartis
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol NOTA
    EUR
  • Novartis
    Börse Gettex System der Börse München
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Quotrix System der Börse Düsseldorf
    Symbol NOT
    EUR
  • Novartis
    Börse Börse Düsseldorf
    Symbol NOTA
    EUR
  • Novartis
    Börse Börse Stuttgart
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Berlin
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Hamburg
    Symbol NOT
    EUR
  • Novartis
    Börse NYSE New York Stock Exchange
    ISIN US66987V1098 WKN: 907122
    Symbol NVS
    USD
  • ISIN CH0012005267 WKN: 904278
    Symbol NOVN
    USD
  • Novartis
    Börse BVMF
  • Novartis
    Börse London Stock Exchange
  • Symbol NOTA
  • Symbol NOTA
  • CHF
  • MXN
  • USD
  • Novartis
    Börse Bolsa de Comercio de Buenos Aires
Firmenname Novan, Inc
Marktkapitalisierung 118.240.562.752 (+- 54%)

Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:

218.646.976 oder 172.940.000.000 oder 181.563.041.280

Mitarbeiter 54.012 (+- 100%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

23 oder 108.000 Mitarbeiter

Anzahl Aktien 2.265.008.000
KGV 17.9
EBITDA -24.745.000
Buchwert 0.02

Novartis underperformed den DAX um -24 % vom 20.10.2020 bis 06.08.2021

Analystenmeinungen

Übersicht

Letzte Communitymeinungen

Ein User hat Novartis abonniert.

Aktionärsstruktur der Novan, Inc

277 News & Informationen zur Novartis Aktie

  • Immutep (ASX:IMM) granted Chinese patent for anti-LAG-3 antibody
    themarketherald.com.au

    Immutep (ASX:IMM) granted Chinese patent for anti-LAG-3 antibody

    Immutep (ASX:IMM) has been granted its fifth patent, with China as the newest office to accept its submission.

  • Asia-Pacific Gene Therapy Markets, 2021-2030 - Product Launches and Grants / Outsourcing of Vector and Gene Therapy Manufacturing
    prnewswire.com

    Asia-Pacific Gene Therapy Markets, 2021-2030 – Product Launches and Grants / Outsourcing of Vector and Gene Therapy Manufacturing

    /PRNewswire/ — The “Asia-Pacific Gene Therapy Market Research Report: Type, Vector Type, Application, End User – Industry Analysis and Demand Forecast to…

  • Pfizer, BioNTech expand covid-19 vaccine manufacturing into Latin America
    livemint.com

    Pfizer, BioNTech expand covid-19 vaccine manufacturing into Latin America

    Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region

  • IBio Appoints William D. Clark To Its Board Of Directors
    thestreet.com

    IBio Appoints William D. Clark To Its Board Of Directors

    BRYAN, Texas, Aug. 26, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer

  • Outlook On The Multiple Myeloma Drugs Global Market To 2026 - By Therapy, Drug Type, End-user, Distribution Channel And Region
    thestreet.com

    Outlook On The Multiple Myeloma Drugs Global Market To 2026 – By Therapy, Drug Type, End-user, Distribution Channel And Region

    DUBLIN, Aug. 25, 2021 /PRNewswire/ — The “Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio
    prnewswire.com

    $ 1.37 bn Growth in Epinephrine Autoinjector Market | Emerging Trends, Company Risk, and Key Executives | Technavio

    /PRNewswire/ — The epinephrine autoinjector market is set to grow by $ 1.37 bn, progressing at a CAGR of over 7.84% during 2021-2025. The report offers an…

  • Global Diuretics (Diuril, Microzide, Indapamide) Market Report 2021: Long-term Forecast to 2025 & 2030
    prnewswire.com

    Global Diuretics (Diuril, Microzide, Indapamide) Market Report 2021: Long-term Forecast to 2025 & 2030

    /PRNewswire/ — The

  • Greatmark Investment Partners, Inc. Buys Discovery Inc, Amgen Inc, The Travelers Inc, Sells Coherent Inc, Gilead Sciences Inc, Teva...
    gurufocus.com

    Greatmark Investment Partners, Inc. Buys Discovery Inc, Amgen Inc, The Travelers Inc, Sells Coherent Inc, Gilead Sciences Inc, Teva Pharmaceutical Industries

    GuruFocus Article or News written by insider and the topic is about:

  • Who Are Pfizer's (PFE) Main Competitors?
    investopedia.com

    Who Are Pfizer's (PFE) Main Competitors?

    Pfizer's biggest competitors in the global pharmaceutical industry are Roche Holding, Eli Lilly, AbbVie, Novartis, and Merck.

  • Global Dermatology Drugs Market to 2027 - Industry Analysis, Trends, Market Size, and Forecasts
    prnewswire.com

    Global Dermatology Drugs Market to 2027 – Industry Analysis, Trends, Market Size, and Forecasts

    /PRNewswire/ — The “Dermatology Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027” report has been added to…

  • Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
    zacks.com

    Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study

    Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.

  • PureTech Health plc : – Half-Year Report
    marketscreener.com

    PureTech Health plc : – Half-Year Report

    Strong capital base and cash runway expected into the first quarter of 2025, with PureTech level cash and cash equivalents of $409.7 million1 and consolidated cash and cash equivalents of $439.8… | August 24, 2021

  • Novartis's Kymriah does not meet primary endpoint in phase III study
    financialpost.com

    Novartis's Kymriah does not meet primary endpoint in phase III study

    ZURICH — Novartis ag said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not…

  • Woodley Farra Manion Portfolio Management Inc Buys Progressive Corp, Raytheon Technologies Corp, International Business Machines Corp,...
    gurufocus.com

    Woodley Farra Manion Portfolio Management Inc Buys Progressive Corp, Raytheon Technologies Corp, International Business Machines Corp, Sells Novartis AG, Eaton Corp PLC, General Electric Co

    GuruFocus Article or News written by insider and the topic is about:

  • Johnson & Johnson : Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to...
    marketscreener.com

    Johnson & Johnson : Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022 (Form 8-K)

    Johnson & Johnson today announced that Mr. Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive… | August 20, 2021

  • Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026
    markets.businessinsider.com

    Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026

    SAN FRANCISCO, Aug. 20, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research comp…

  • Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026
    prnewswire.com

    Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis - Forecast to 2026
    markets.businessinsider.com

    Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis – Forecast to 2026

    DUBLIN, Aug. 19, 2021 /PRNewswire/ — The 'Global Atopic Dermatitis Drugs Market (2021-2026) by Drug Class, Route of Administration, Geography, Co…

  • Global Intranasal Drug Delivery Market Forecast to 2027: Burgeoning Geriatric Populace Spurs Growing Demand
    prnewswire.com

    Global Intranasal Drug Delivery Market Forecast to 2027: Burgeoning Geriatric Populace Spurs Growing Demand

    /PRNewswire/ — The

  • Global Intranasal Drug Delivery Market Forecast To 2027: Burgeoning Geriatric Populace Spurs Growing Demand
    thestreet.com

    Global Intranasal Drug Delivery Market Forecast To 2027: Burgeoning Geriatric Populace Spurs Growing Demand

    DUBLIN, Aug. 19, 2021 /PRNewswire/ — The

  • BlueSphere Bio appoints industry veteran Jonathan Peacock
    markets.businessinsider.com

    BlueSphere Bio appoints industry veteran Jonathan Peacock

    PITTSBURGH, Aug. 19, 2021 /PRNewswire/ — BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in it…

  • Optiver Holding B.V. Buys Royal Dutch Shell PLC, Banco Santander SA, ArcelorMittal SA, Sells ASML Holding NV, BP PLC, Petroleo Brasileiro...
    gurufocus.com

    Optiver Holding B.V. Buys Royal Dutch Shell PLC, Banco Santander SA, ArcelorMittal SA, Sells ASML Holding NV, BP PLC, Petroleo Brasileiro SA Petrobras

    GuruFocus Article or News written by insider and the topic is about:

  • Global Regenerative Medicine Markets, 2021-2029: Focus On Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologics
    thestreet.com

    Global Regenerative Medicine Markets, 2021-2029: Focus On Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologics

    DUBLIN, Aug. 18, 2021 /PRNewswire/ — The

  • Global Regenerative Medicine Markets, 2021-2029: Focus on Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologics
    prnewswire.com

    Global Regenerative Medicine Markets, 2021-2029: Focus on Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologics

    /PRNewswire/ — The

  • Cholesterol Lowering Drugs Market Report 2021-2028| Size, Share, Growth, Trends, Revenue, Competitive Analysis, Forecast
    globenewswire.com

    Cholesterol Lowering Drugs Market Report 2021-2028| Size, Share, Growth, Trends, Revenue, Competitive Analysis, Forecast

    Top Players Covered in the Cholesterol Lowering Drugs Market Research Report Are AstraZeneca, Pfizer Inc., Novartis AG, AbbVie Inc., Sun Pharmaceuticals…

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

  • Pfizer: The Rally Is Far From Finished
    gurufocus.com

    Pfizer: The Rally Is Far From Finished

    GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Novartis Aktie

Das Unternehmen Novan, Inc aus Schweiz beschäftigt 54.012 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Medizinische Produkte / Medizintechnik, Biotechnologie, Pharma tätig.

Die Novartis Aktie konnte seit dem 20.10.2020 leider keine Rendite erwirtschaften. Die Kursverluste lagen bei -1%.

Das Unternehmen Novan, Inc ist in mehr als 80 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (CH) SMI® gewichtet Novartis mit 16,90% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Novartis Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen Novan, Inc am höchsten gewichtet ist Insgesamt in 80 ETFs enthalten

Dir gefallen die Informationen zu Novartis?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Novartis?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Novartis?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu Novartis?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba